https://www.pharmaradar360.com/article/abf22637926e2301PharmaRadar360en2026-04-26T11:00:55.000Z“What Got Us Here, Won’t Get Us There,” and Other Insights on the Clinical Research Workforce Shared at ACRP 2026https://www.pharmaradar360.com/article/115ac4107c2b3d15PharmaRadar360en2026-04-26T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/a8b8c7fbd739a179PharmaRadar360en2026-04-26T00:00:00.000Znatco records %e2%82%b91463 crore consolidated revenue and %e2%82%b9517 9 crore of profit after tax for q2fy26https://www.pharmaradar360.com/article/2c32598eab7030d2PharmaRadar360en2026-04-26T00:00:00.000Znatco receives tentative approval for erdafitinib tablets generic of balversa from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/0ab3c84dc961eb04PharmaRadar360en2026-04-26T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/90147a96daafe8b8PharmaRadar360en2026-04-26T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/6ce764b35bad1804PharmaRadar360en2026-04-26T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/c3aa07f7f31cc43bPharmaRadar360en2026-04-26T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/4b3724235ee61c46PharmaRadar360en2026-04-26T00:00:00.000Znatco announces launch of its everolimus tablets 1 mg generic of zortresshttps://www.pharmaradar360.com/article/223fd89565a39b36PharmaRadar360en2026-04-26T00:00:00.000Zlegal update regarding risdiplamhttps://www.pharmaradar360.com/article/ade6c36a4ccc739aPharmaRadar360en2026-04-26T00:00:00.000Zintimation under regulation 30 of sebi listing obligations and disclosure requirements regulations 2015 2https://www.pharmaradar360.com/article/6325e0fcb7381949PharmaRadar360en2026-04-26T00:00:00.000Zdisclosure under regulation 30 of the sebi listing obligations and disclosure requirements regulations 2015https://www.pharmaradar360.com/article/f9bc749287adfe67PharmaRadar360en2026-04-26T00:00:00.000Zadcock ingram completes delisting from jse natco pharma acquires 35 75 stakehttps://www.pharmaradar360.com/article/51dbe4fb98a4481ePharmaRadar360en2026-04-26T00:00:00.000Z6203https://www.pharmaradar360.com/article/ce9b576e334e74ffPharmaRadar360en2026-04-26T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/35304e55eb795dc7PharmaRadar360en2026-04-25T16:30:00.000ZMedtronic announces key Affera™ clinical study milestones for Sphere-9™ and Sphere-360™ catheters as global adoption continueshttps://www.pharmaradar360.com/article/3d29ab051be6ae2aPharmaRadar360en2026-04-25T00:00:00.000ZCleveland Clinic-led Trial Shows Pulsed Field Ablation Procedure More Effective Than Medications for Persistent Atrial Fibrillationhttps://www.pharmaradar360.com/article/8da3013fbc220862PharmaRadar360en2026-04-24T20:21:36.000ZSuspensión de Servicios